Dr. Maloney is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
825 Eastlake Ave E
Seattle, WA 98109Phone+1 206-667-5616Fax+1 206-667-6124- Is this information wrong?
Summary
- Dr. David Maloney is an oncologist in Seattle, WA and is affiliated with multiple hospitals in the area, including Seattle Cancer Care Alliance, Seattle Children's Hospital, and University of Washington Medical Center. He received his medical degree from Stanford University School of Medicine and has been in practice 32 years. He specializes in hematologic oncology and is experienced in hematologic oncology.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1988 - 1994
Brigham and Women's HospitalResidency, Internal Medicine, 1985 - 1988
Stanford University School of MedicineClass of 1985
Certifications & Licensure
WA State Medical License 1994 - 2024
CA State Medical License 1988 - Present- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2008-2014
- America's Top Doctors for Cancer Castle Connolly, 2007-2013
Clinical Trials
- Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation Start of enrollment: 1996 Mar 01
- High-Dose Chemotherapy Followed by Total-Body Irradiation and Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia Start of enrollment: 1995 Oct 01
- Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma Start of enrollment: 1997 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: A real-world study.Lorenzo Iovino, Qian Vicky Wu, Jenna Voutsinas, Lorena Panaite, Erin Mullane, Ryan C Lynch, Chaitra Ujjani, Stephen D Smith, Ajay K Gopal, Brian G Till, Filippo Milano...> ;Journal of cellular and molecular medicine. 2022 Dec 1
- 3 citationsImpact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL.Jordan Gauthier, Nicolas Gazeau, Alexandre V Hirayama, Joshua A Hill, Vicky Wu, Aisling Cearley, Paula Perkins, Angela Kirk, Mazyar Shadman, Victor A Chow, Ajay K Gopa...> ;Blood. 2022 Jun 30
- Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with r...Manali Kamdar, Scott R Solomon, Jon Arnason, Patrick B Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Il...> ;Lancet (London, England). 2022 Jun 18
- Join now to see all
Journal Articles
- Long Term Follow-up of Tandem Autologous-Allogeneic Hematopoietic Cell Transplantation for Multiple MyelomaParameswaran Hari, Brenda M Sandmaier, Pamela S Becker, Leona Holmberg, Damian J Green, Peter A McSweeney, David G Maloney, Thomas R Chauncey, Haematologica
- Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity After Adoptive Immunotherapy with CD19 CAR-T CellsMark Wurfel, David G Maloney, Kathleen R Fink, W Conrad Liles, Cameron J Turtle, Cecilia Yeung, Clinical Cancer Research
Abstracts/Posters
- Response to Bcma CAR-T Cells Correlates with Pretreatment Target Antigen Density and Is Improved By Small Molecule Inhibition of Gamma SecretaseDavid G. Maloney, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival after Repeat Infusions of CD19 CAR-T CellsClinically Relevant AbstractDavid G. Maloney, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Includi...David G. Maloney, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Hit the Ground Running: What You Need to Know About CAR T-Cell Therapy61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B-Cell Lymphoma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Immunotherapy with T-Cells Engineered with a Chimeric Antigen Receptor Bearing a Human CD19-Binding Single Chain Variable Fragment for Relapsed or Refractory Acute Lym...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
Expert Highlights CAR T-cell BreakthroughsNovember 1st, 2017
Fred Hutch Unveils First-of-Its-Kind Immunotherapy Clinic, Named After Bezos FamilyNovember 1st, 2016
A Medical Breakthrough That Hacks Genes to Fight Cancer Just Got Approved, and It's the Beginning of 'A Big New Field of Medicine'September 1st, 2017- Join now to see all
Grant Support
- Allogeneic HCT For Hematologic Malignancies: Pharmacologic ManipulationsNational Cancer Institute2009–2012
- Mixed Chimerism In The Treatment Of B-Cell MalignanciesNational Cancer Institute2004–2008
- Anti-Cd20 Antibody Therapy Of Nhl-- Mechanism Of ActionNational Cancer Institute2000–2002
- Myeloma Idiotype VaccinesNational Cancer Institute1997
Hospital Affiliations
UW Medicine/University of Washington Medical CenterSeattle, Washington
Fred Hutchinson Cancer CenterSeattle, Washington
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
